BRPI0903901A2 - composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf - Google Patents

composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf

Info

Publication number
BRPI0903901A2
BRPI0903901A2 BRPI0903901A BRPI0903901A BRPI0903901A2 BR PI0903901 A2 BRPI0903901 A2 BR PI0903901A2 BR PI0903901 A BRPI0903901 A BR PI0903901A BR PI0903901 A BRPI0903901 A BR PI0903901A BR PI0903901 A2 BRPI0903901 A2 BR PI0903901A2
Authority
BR
Brazil
Prior art keywords
permeability
availability
methods
pathological angiogenesis
activation
Prior art date
Application number
BRPI0903901A
Other languages
English (en)
Inventor
Jones Christopher
Li Dean
London Nyall
Original Assignee
Univ Of Utah Res Foudation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Utah Res Foudation filed Critical Univ Of Utah Res Foudation
Publication of BRPI0903901A2 publication Critical patent/BRPI0903901A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
BRPI0903901A 2008-04-16 2009-04-16 composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf BRPI0903901A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4558008P 2008-04-16 2008-04-16
US7388008P 2008-06-19 2008-06-19
PCT/US2009/040848 WO2009129408A2 (en) 2008-04-16 2009-04-16 Compositions and methods for treating pathologic angiogenesis and vascular permeability

Publications (1)

Publication Number Publication Date
BRPI0903901A2 true BRPI0903901A2 (pt) 2017-05-23

Family

ID=41199735

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0903901A BRPI0903901A2 (pt) 2008-04-16 2009-04-16 composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf

Country Status (8)

Country Link
US (1) US20100222401A1 (pt)
EP (1) EP2262524A4 (pt)
JP (1) JP2011518178A (pt)
KR (1) KR20100133881A (pt)
CN (1) CN101687014A (pt)
BR (1) BRPI0903901A2 (pt)
CA (1) CA2693001A1 (pt)
WO (1) WO2009129408A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073441A2 (en) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
US20110087603A1 (en) * 2009-10-13 2011-04-14 Google Inc. Cloud based media player and offline media access
US8620879B2 (en) * 2009-10-13 2013-12-31 Google Inc. Cloud based file storage service
CN102233134A (zh) * 2010-04-30 2011-11-09 中国科学院上海生命科学研究院 Slit-robo介导的淋巴管形成及其应用
US8399404B2 (en) 2010-06-15 2013-03-19 The Hospital For Sick Children Methods and uses for inhibiting platelet coagulation
US10561707B2 (en) * 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
EP3148986A4 (en) * 2014-05-27 2018-01-10 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
SG11201706799YA (en) * 2015-03-02 2017-09-28 Univ Illinois Peptides for inhibiting angiogenesis
CN105726534A (zh) * 2016-02-17 2016-07-06 上海交通大学医学院附属仁济医院 SecinH3在制备抑制胃酸分泌药物中的应用
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
CN108929383B (zh) 2017-05-26 2021-10-15 阿思科力(苏州)生物科技有限公司 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
US11077422B2 (en) * 2017-06-16 2021-08-03 Aquablok, Ltd. Spalling composite particles and methods of using them
CN108364289B (zh) * 2018-03-02 2021-05-14 成都斯斐德科技有限公司 Ivoct图像易损斑块自动检测方法
CN108715862A (zh) * 2018-05-28 2018-10-30 上海海洋大学 ddx19基因缺失斑马鱼突变体的制备方法
CA3154805A1 (en) * 2019-10-18 2021-04-22 Iosif PEDIADITAKIS Brain-chip modeling neurodegeneration and neuroinflammation in parkinson's disease
WO2021184059A1 (en) * 2020-03-14 2021-09-23 Newsouth Innovations Pty Limited Treatment methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US6372958B1 (en) * 1999-05-26 2002-04-16 The University Of Utah Research Foundation Transgenic mouse with endogenous endoglin gene disruption
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
US7402660B2 (en) * 2000-08-02 2008-07-22 The Johns Hopkins University Endothelial cell expression patterns
WO2003075860A2 (en) * 2002-03-08 2003-09-18 Abgent, Inc. Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
CA2490713A1 (en) * 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
DE102004055998A1 (de) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie
DE102006054205A1 (de) * 2006-11-15 2008-05-29 Rheinische Friedrich-Wilhelms Universität Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit
WO2008073441A2 (en) * 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
BRPI0915287A2 (pt) * 2008-12-12 2016-02-16 Univ Utah Res Found usos de pelo menos um polipeptídeo slit, de pelo menos um inibidor de pelo menos um fator de troca arf gtp (arf-gef), e, de um composto

Also Published As

Publication number Publication date
US20100222401A1 (en) 2010-09-02
CA2693001A1 (en) 2009-10-22
EP2262524A2 (en) 2010-12-22
KR20100133881A (ko) 2010-12-22
CN101687014A (zh) 2010-03-31
WO2009129408A2 (en) 2009-10-22
EP2262524A4 (en) 2012-07-11
JP2011518178A (ja) 2011-06-23
WO2009129408A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
BRPI0903901A2 (pt) composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf
DK2421406T4 (da) Frigivelses-forhindringssystem til vægskabe
FR2934481B1 (fr) Etagere, en particulier pour des installations refrigerees.
BRPI0817288A2 (pt) Dispositivos vasculares trançados não tendo grampos de extremidade.
DK3329888T3 (da) System til indføring af trommehindetrykudligningsrør
BRPI0919914A2 (pt) sistema de ajuste da rgulação de tempo automático para sensores de ocupação.
BRPI1014797A2 (pt) método de cálculo de via, elemento de cálculo de via dispositivo de nó e sistema de rede.
FR2935242B1 (fr) Etagere, en particulier pour installations refrigerees
FR2920087B1 (fr) Dispositif de prevention de fuites urinaires
BRPI0919291A2 (pt) película parcialmente metalizada que tem propriedades de barreira.
BRPI1005675A2 (pt) benzenossulfonamidas bloqueadoras dos canais de cálcio
BR112014004935A2 (pt) filmes de polímero de multimarcas tendo propriedades de barreira aprimoradas
BRPI0904329A2 (pt) Método de avaliação de sinal de reprodução, unidade de avaliação de sinal de reprodução e dispositivo de disco adotando o mesmo
BRPI0907930A2 (pt) Garfo deslizante com nervuras internas tendo revestimento permanente e método relacionado.
BRPI0922341A2 (pt) composição farmacêutica revestida em fusão com liberação rápida.
BR112012013829A2 (pt) "sistema de freio a disco em banho de óleo".
FR2929815B1 (fr) Etagere, en particulier pour des installations refrigerees.
DK2950822T3 (da) Farmaceutisk sammensætning til beskyttelse af sår, tilvejebringelse af hæmostase eller forebyggelse af adhæsion i mave-tarm-kanalen
BRPI0719019A2 (pt) Sistema de drenagem para uma lavadora de louças
BRPI0924646A2 (pt) películas de não pvc tendo camada de barreira
DK2387591T3 (da) Copolymer til inhibering af uorganiske aflejringer
DK2294254T3 (da) Polyethylengarn med ultrahøj molekylvægt
FR2929814B1 (fr) Etagere, en particulier pour des installations refrigerees
FR2932525B3 (fr) Protecteur pour terrasses,balcons et similaires.
FR2896161B1 (fr) Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]